



# Division of Medical Services Pharmacy Program

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437  
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



## ARKANSAS MEDICAID DUR/DRC BOARD QUARTERLY DRUG UPDATE

July 19, 2023 8:30 A.M. – 12:30 P.M.

VIRTUAL ZOOM MEETING LINK

[https://us02web.zoom.us/j/82974494973?tk=UTP2QJLpVBCZQ6BpgAqXzHZq0bdUh9oy4Ct39Yhate4.DQMAAAATUapQ\\_RZoUnU3cURHLVRLLeWZ0OGV0dUdTUDBnAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA&pwd=cU93SzNtOERTeFR0RFZpZWdqR1BiQT09](https://us02web.zoom.us/j/82974494973?tk=UTP2QJLpVBCZQ6BpgAqXzHZq0bdUh9oy4Ct39Yhate4.DQMAAAATUapQ_RZoUnU3cURHLVRLLeWZ0OGV0dUdTUDBnAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA&pwd=cU93SzNtOERTeFR0RFZpZWdqR1BiQT09)

**\*\*TENTATIVE AGENDA IS SUBJECT TO CHANGE\*\***

### I. OUTSIDE SPEAKERS

**DUR/DRC Board Bylaws, Section 7.02 Outside Speakers** -- Outside speakers with clinical or scientific credentials or patient experience pertinent to a product or topic that is posted on the upcoming DUR/DRC Board meeting agenda may request to speak on that product or topic. Requests to speak at the DUR/DRC Board meeting must be made in writing to the DUR Chairperson at least two (2) weeks before the DUR/DRC Board meeting date, and should include:

1. The speaker's name, title, relevant credentials, and organization;
2. Contact information for the speaker including address, telephone number, and email;
3. The agenda item(s) which the speaker intends to address;
4. Prepared comments; and
5. Any educational materials for Board members in advance of the meeting.

This information shall be included in information sent to Board members two (2) weeks prior to the Board meeting. Presentations or public comments given at the DUR/DRC Board meeting are limited to a total of six (6) minutes per drug, which may be shared by multiple speakers. This time limit does not include responses to any questions raised by DUR/DRC Board members during the course of the meeting.

**NOTE: Due to the amount of medications on the agenda, the comment time may have to be decreased.**

A copy of the proposed criteria for the specific agenda item on which an individual requests to speak may be requested from the Chairperson three (3) weeks prior to the DUR/DRC Board meeting. The information will be in draft form and may be changed by the DUR/DRC Board prior to being finalized. As such, the draft criteria should not be shared with clinicians or patients.

### II. UNFINISHED / OLD BUSINESS AND GENERAL ORDERS / AND PROPOSALS TO REVISE PREVIOUS CRITERIA

- A. ANNOUNCEMENTS
- B. APPROVAL OF THE MINUTES FROM THE PREVIOUS MEETING.
- C. UPDATE ON SYSTEM EDITS, IMPLEMENTATIONS, OR FOLLOW-UP ITEMS.
  - 1) Follow-up items from April 19, 2023 DUR/DRC Board: None
  - 2) Implementation information from April 19, 2023 DUR/DRC Board
- D. GENERAL INFORMATION
- E. PDL CLASS REVIEW WITHOUT CRITERIA (see specific medications on page 3)
  - 1) Short-acting beta agonists
- F. PDL CLASS REVIEW WITH CRITERIA (see specific medications on page 3)
  - 1) Antidepressants
  - 2) Long-acting injectable antipsychotics
  - 3) Immunomodulators, asthma
  - 4) ADD/ADHD agents
  - 5) Narcolepsy agents
  - 6) Atopic dermatitis
  - 7) HIV (new class)

<https://humanservices.arkansas.gov/>

Protecting the vulnerable, fostering independence and promoting better health



**Division of Medical Services  
Pharmacy Program**

P.O. Box 1437, Slot S415 · Little Rock, AR 72203-1437  
501-683-4120 · Fax: 501-683-4124 or 1-800-424-5851



- G. PROPOSED CHANGES TO EXISTING CRITERIA and EDITS, INCLUDING POINT OF SALE (POS) CRITERIA, MANUAL REVIEW PA CRITERIA, OR CLAIM EDITS:
- 1) Update to new-to-market policy
  - 2) RSV (tentative)

**III. NEW BUSINESS**

- A. PROPOSED NEW CLINICAL POINT OF SALE CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
- B. MANUAL REVIEW PROPOSED CRITERIA WITH OR WITHOUT ADDITIONAL CLAIM EDITS:
- 1) Daybue™ (trofinetide) solution
  - 2) Joenja® (leniolisib) tablet
  - 3) Vowst™ (fecal microbiota spores, live-brpk) capsule
  - 4) Furoscix® (furosemide) injection
  - 5) Veozah™ (fezolinetant) tablet
- C. PROPOSED NEW CLAIM EDITS (QUANTITY, DAILY DOSE, ACCUMULATION, GENDER, AGE): None
- D. ProDUR REPORT UPDATE
- E. RDUR REPORT UPDATE



<b>PDL THERAPEUTIC CLASSES UNDER REVIEW</b>
<b>Short-acting beta agonists:</b> albuterol inhalation solution, levalbuterol HFA inhaler, ProAir Digihaler, ProAir RespiClick, Proventil HFA, Ventolin HFA, Xopenex HFA, Xopenex inhalation solution
<b>Antidepressants:</b> Aplenzin tablet, Auvelity tablet, bupropion tablet, bupropion ER tablet, bupropion SR tablet, citalopram tablet, citalopram capsule, citalopram solution, Cymbalta capsule, desvenlafaxine ER, duloxetine capsule, Drizalma sprinkle, escitalopram tablet, Fetzima capsule, fluoxetine capsule, fluoxetine tablet, fluoxetine solution, fluvoxamine, fluvoxamine ER, Forfivo XL tablet, Marplan tablet, mirtazapine tablet, mirtazapine ODT, Nardil tablet, nefazodone tablet, paroxetine tablet, paroxetine CR tablet, paroxetine suspension, paroxetine capsule, Paxil IR tablet, Paxil CR tablet, Paxil suspension, Pexeva tablet, phenelzine tablet, Pristiq ER tablet, Remeron SolTab, Savella tablet, selegiline capsule, selegiline tablet, sertraline tablet, Spravato, tranylcypromine tablet, trazodone, Trintellix tablet, venlafaxine ER capsule, venlafaxine tablet, Viibryd tablet, vilazodone tablet
<b>Long-acting injectable antipsychotics:</b> Abilify Maintena, Abilify Asimtufii, Aristada, Aristada Initio, Fluphenazine decanoate, haloperidol decanoate, Invega Sustenna, Invega Trinza, Invega Hafyera, Perseris ER, Risperdal Consta, Zyprexa Relprevv, Uzedly
<b>Immunomodulators, asthma:</b> Dupixent, Fasenra, Nucala, Tezspire, Xolair
<b>ADD/ADHD agents:</b> Adderall IR tablet, Adderall XR capsule, Adhansia XR, Adzenys, Aptensio XR, atomoxetine, Azstarys, clonidine ER, Concerta, Cotempla XR ODT, Daytrana, Desoxyn, Dexedrine, dexamethylphenidate, dexamethylphenidate XR, dextroamphetamine tablet, dextroamphetamine capsule, dextroamphetamine solution, Dyanavel XR tablet, Dyanavel XR solution. Evekeo, Evekeo ODT, Focalin, Focalin XR, Intuniv, Jornay PM, Kapvay, methylphenidate, methylphenidate chewable, methylphenidate ER, methylphenidate SR, mixed amphetamine salts IR tablet, mixed amphetamine salts XR capsule, methamphetamine, methylin solution, Mydayis ER, Procentra solution, Qelbree, Quillichew ER, Quilivant XR, Relexxii, Ritalin, Ritalin LA, Strattera, Vyvanse, Xelstrym, Zenzedi
<b>Narcolepsy agents:</b> Lumryz, Nuvigil, Provigil, Sunosi, Wakix, Xyrem, Xywav
<b>Immunomodulators, atopic dermatitis:</b> Adbry, Cinqo, Dupixent, Elidel, Eucrisa, Opzelura, Protopic, Rinvoq
<b>HIV:</b> abacavir, abacavir/lamivudine, Apretude, Aptivus, atazanavir, Atripla, Biktarvy, Cabenuva, Cimduo, Combivir, Complera, Delstrigo, Descovy, Didanosine, Dovato, Edurant, efavirenz, efavirenz/emtricitabine/tenofovir, efavirenz/lamivudine/tenofovir, emtricitabine/tenofovir, emtricitabine, Emtriva, Epivir, Epzicom, etravirine, Evotaz, fosamprenavir, Fuzeon, Genvoya, Intelence, Invirase, Isentress, Isentress HD, Juluca, Kaletra, lamivudine, lamivudine/zidovudine, Lexiva, lopinavir/ritonavir, maraviroc tablet, Nevirapine, Nevirapine ER, Norvir, Odefsey, Pifeltro, Prezcobix, Prezista, Reyataz, Retrovir, Ritonavir, Rukobia, Selzentry tablet, Selzentry solution, Stavudine, Stribild, Sunlenca, Sustiva, Symfi, Symfi Lo, Symtuza, Temixys, tenofovir, Tivicay, Tivicay PD, Triumeq, Triumeq PD, Trizivir, Truvada, Tybost, Viracept, Viread, Vocabria, Ziagen, Zidovudine